Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Equity Average (2016 - 2025)

Aptevo Therapeutics' Equity Average history spans 10 years, with the latest figure at $12.0 million for Q3 2025.

  • For Q3 2025, Equity Average rose 169.23% year-over-year to $12.0 million; the TTM value through Sep 2025 reached $12.0 million, up 169.23%, while the annual FY2024 figure was $8.5 million, 43.78% down from the prior year.
  • Equity Average for Q3 2025 was $12.0 million at Aptevo Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $20.6 million in Q1 2023 and bottomed at -$2.3 million in Q1 2022.
  • The 5-year median for Equity Average is $10.6 million (2021), against an average of $10.1 million.
  • The largest annual shift saw Equity Average plummeted 117.23% in 2022 before it surged 983.25% in 2023.
  • A 5-year view of Equity Average shows it stood at $4.3 million in 2021, then surged by 296.52% to $16.9 million in 2022, then decreased by 20.15% to $13.5 million in 2023, then tumbled by 65.94% to $4.6 million in 2024, then surged by 160.66% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Equity Average are $12.0 million (Q3 2025), $2.5 million (Q2 2025), and $1.6 million (Q1 2025).